China Pharma Holdings, Inc. (NYSEAMERICAN:CPHI – Get Rating) saw a significant drop in short interest during the month of December. As of December 30th, there was short interest totalling 244,600 shares, a drop of 51.8% from the December 15th total of 507,100 shares. Based on an average daily volume of 2,160,000 shares, the short-interest ratio is presently 0.1 days. Currently, 0.9% of the company's stock are short sold.

China Pharma Stock Performance

CPHI remained flat at $0.11 during trading on Wednesday. 1,588,857 shares of the company were exchanged, compared to its average volume of 1,853,631. The firm has a market capitalization of $5.43 million, a P/E ratio of -1.31 and a beta of 0.62. China Pharma has a fifty-two week low of $0.08 and a fifty-two week high of $0.53.

China Pharma (NYSEAMERICAN:CPHI – Get Rating) last issued its earnings results on Monday, November 14th. The company reported ($0.02) earnings per share for the quarter. The firm had revenue of $1.97 million for the quarter. China Pharma had a negative return on equity of 81.00% and a negative net margin of 45.71%.

China Pharma Company Profile

China Pharma Holdings, Inc engages in the development, manufacture, and marketing of pharmaceutical products. The firm's product portfolio includes Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases, Anti-infection and Respiratory Diseases, Digestive Diseases, Comprehensive Healthcare, and Protective Products.

See Also

• Get a free copy of the StockNews.com research report on China Pharma (CPHI)
• Stocks Slide, Economic Report Paints Gloomy Picture For Economy
• What does Nu Holdings Stock Have To Do With Warren Buffett?
• J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
• Is Intel Stock On The Verge Of Breaking Out?
• Does it Matter Folks Aren't "Starry-Eyed" Over Pepsi's New Soda?

Receive News & Ratings for China Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Pharma and related companies with MarketBeat.com's FREE daily email newsletter.